Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RC48-ADC in salivary gland tumors
NCT05601401Phase 2Unknown
- Sponsor
- Peking Union Medical College Hospital
- Start
- Mar 2022
- Primary completion
- Mar 2023
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 2 trial of disitamab vedotin in salivary gland cancer (SGC), sponsored by Peking Union Medical College Hospital. Status: unknown.
02
Drugs
disitamab vedotin
03
Conditions
salivary gland cancer (SGC)
Beyond the preview
Go deeper on NCT05601401.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05601401.